By Fineline Cube Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy, in individuals with early Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC) 2026. Based on consistent evidence from Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.
Clinical Development Milestone
| Item | Detail |
|---|---|
| Study Name | Phase 2 CELIA |
| Indication | Early Alzheimer’s disease |
| Patient Population | Individuals with early Alzheimer’s disease |
| Primary Endpoints | ADAS-Cog13, MMSE, CDR-SB cognitive assessments |
| Key Results | 42% slowing on ADAS-Cog13, 50% on MMSE, 26% on CDR-SB (60 mg dose) |
| Next Phase | Confirmatory Phase 3 development |
Drug Profile & Mechanism of Action
- Molecule: Investigational antisense oligonucleotide (ASO) therapy (BIIB080)
- Target: Microtubule-associated protein tau (MAPT) mRNA
- Mechanism: Reduces production of tau protein by targeting MAPT mRNA
- Innovation: First ASO therapy demonstrating consistent cognitive benefit across multiple endpoints in early Alzheimer’s disease
Clinical Evidence – Phase 2 CELIA Study
| Endpoint | 60 mg Dose Result | Clinical Significance |
|---|---|---|
| ADAS-Cog13 | 42% slowing of clinical decline | Primary cognitive assessment tool for Alzheimer’s |
| MMSE | 50% slowing of clinical decline | Standard screening measure for cognitive impairment |
| CDR-SB | 26% slowing of clinical decline | Global measure of dementia severity |
| Dose Response | Efficacy demonstrated across all studied doses at 18 months | Consistent results across prespecified clinical endpoints |
The study demonstrated that diranersen’s 60 mg dose showed the strongest response, with statistically significant slowing of clinical decline across all major cognitive endpoints, representing a potentially meaningful clinical benefit for patients with early Alzheimer’s disease.
Market Impact & Therapeutic Landscape
- Alzheimer’s Disease Market: With limited disease-modifying options and significant unmet need, a tau-targeting therapy showing cognitive benefit represents a major therapeutic advance
- Competitive Edge: Unlike amyloid-focused therapies, diranersen targets tau pathology, which correlates more closely with cognitive decline in Alzheimer’s disease
- Strategic Positioning: Positions Biogen to potentially offer both amyloid and tau-targeting therapies, creating a comprehensive Alzheimer’s treatment portfolio
Forward‑Looking Statements
This brief contains forward‑looking statements regarding diranersen’s clinical development and regulatory pathway. Actual results may differ due to risks including Phase 3 trial outcomes, regulatory approvals, and competitive dynamics.-Fineline Info & Tech